{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:33:59Z","timestamp":1789788839979,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020043","name":"Yeditepe \u00dcniversitesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020043","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bbrc.2025.152473","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T15:13:05Z","timestamp":1754925185000},"page":"152473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Combination of Berberine and NVP-BEZ235 inhibits metastasis of triple-negative breast cancer MDA-MB-231 cell line"],"prefix":"10.1016","volume":"781","author":[{"given":"Zuleyha","family":"Demirci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3375-8956","authenticated-orcid":false,"given":"Gamze","family":"Yesilay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbaros","family":"Nalbantoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9216-6336","authenticated-orcid":false,"given":"Zeynep Busra","family":"Bolat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2025.152473_bib1","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.ajpath.2017.03.016","article-title":"The spectrum of triple-negative breast disease: high- and low-grade lesions","volume":"187","author":"Geyer","year":"2017","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbrc.2025.152473_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00031","article-title":"Molecular mechanisms and emerging therapeutic targets of triple-negative breast cancer metastasis","volume":"8","author":"Neophytou","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2025.152473_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2011.00051","article-title":"PI3K\/AKT\/mTOR pathway in angiogenesis","volume":"4","author":"Karar","year":"2011","journal-title":"Front. Mol. Neurosci."},{"issue":"2 33","key":"10.1016\/j.bbrc.2025.152473_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/onc.2012.572","article-title":"Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer","volume":"33","author":"Montero","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2025.152473_bib5","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2025.152473_bib6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s10637-015-0313-8","article-title":"A phase I trial of ANG1\/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008\/NCI\u266f9041)","volume":"34","author":"Chiu","year":"2016","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.bbrc.2025.152473_bib7","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00280-016-2987-9","article-title":"Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors","volume":"77","author":"Tamura","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.152473_bib8","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.21873\/anticanres.11212","article-title":"Phase I study of the Pan-PI3K inhibitor Buparlisib in adult Chinese patients with advanced solid tumors","volume":"36","author":"Wu","year":"2016","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2025.152473_bib9","doi-asserted-by":"crossref","first-page":"8022","DOI":"10.1158\/0008-5472.CAN-08-1385","article-title":"NVP-BEZ235, a dual PI3K\/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations","volume":"68","author":"Serra","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2025.152473_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1146\/annurev-med-062913-051343","article-title":"The PI3K\/AKT pathway as a target for cancer treatment","volume":"67","author":"Mayer","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bbrc.2025.152473_bib11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/2211-5463.12806","article-title":"The PI3K\/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells","volume":"10","author":"Cai","year":"2020","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.bbrc.2025.152473_bib12","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1634\/theoncologist.2017-0144","article-title":"Phase II study of BEZ235 versus everolimus in patients with mammalian target of rapamycin inhibitor\u2010na\u00efve advanced pancreatic neuroendocrine tumors","volume":"23","author":"Salazar","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.bbrc.2025.152473_bib13","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1158\/1535-7163.MCT-11-0792","article-title":"PI3K inhibitors for cancer treatment: five years of preclinical and clinical research after BEZ235","volume":"10","author":"Maira","year":"2011","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.bbrc.2025.152473_bib14","doi-asserted-by":"crossref","first-page":"8097","DOI":"10.1158\/0008-5472.CAN-10-1814","article-title":"Activity of the novel dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia","volume":"70","author":"Chiarini","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2025.152473_bib15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejphar.2015.05.068","article-title":"Current knowledge and pharmacological profile of berberine: an update","volume":"761","author":"Kumar","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.152473_bib16","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.5114\/aoms\/132969","article-title":"Berberine induces apoptosis and arrests the cell cycle in multiple cancer cell lines","volume":"19","author":"Li","year":"2023","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.bbrc.2025.152473_bib17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejphar.2010.07.037","article-title":"Berberine induces apoptosis in breast cancer cells (MCF-7) through mitochondrial-dependent pathway","volume":"645","author":"Patil","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.152473_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217019","article-title":"Unlocking the potential of Berberine: advancing cancer therapy through chemosensitization and combination treatments","volume":"597","author":"Sajeev","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2025.152473_bib19","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3892\/ol.2012.644","article-title":"Berberine sensitizes mutliple human cancer cells to the anticancer effects of doxorubicin in vitro","volume":"3","author":"Tong","year":"2012","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bbrc.2025.152473_bib20","first-page":"273","article-title":"Combination of Doxorubicin and berberine generated synergistic anticancer effect on breast cancer cells through down-regulation of nanog and miRNA-21 gene expression","volume":"11","author":"Ebeid","year":"2020","journal-title":"Middle East J. Cancer"},{"key":"10.1016\/j.bbrc.2025.152473_bib21","article-title":"Anticancer efficiency of doxorubicin and berberine-loaded PCL nanofibers in preventing local breast cancer recurrence","volume":"67","author":"Mozaffari","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.bbrc.2025.152473_bib22","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2020.12189","article-title":"Synergistic antitumor effect of dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with cisplatin on drug-resistant non-small cell lung cancer cell","volume":"20","author":"Zhu","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bbrc.2025.152473_bib23","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bbrc.2025.152473_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.bbrc.2025.152473_bib25","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3390\/nu6041618","article-title":"Selected activities of citrus maxima merr. Fruits on human endothelial cells: enhancing cell migration and delaying cellular aging","volume":"6","author":"Buachan","year":"2014","journal-title":"Nutrients"},{"key":"10.1016\/j.bbrc.2025.152473_bib26","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1159\/000487171","article-title":"Berberine suppresses cell motility through downregulation of TGF-\u03b21 in triple negative breast cancer cells","volume":"45","author":"Kim","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.bbrc.2025.152473_bib27","doi-asserted-by":"crossref","first-page":"5915","DOI":"10.1016\/j.bmc.2010.06.085","article-title":"8, 8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models","volume":"18","author":"Cheng","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbrc.2025.152473_bib28","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.biopha.2018.07.019","article-title":"Synergy of theophylline reduces necrotic effect of berberine, induces cell cycle arrest and PARP, HMGB1, Bcl-2 family mediated apoptosis in MDA-MB-231 breast cancer cells","volume":"106","author":"Hashemi-Niasari","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbrc.2025.152473_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.phyplu.2022.100265","article-title":"In vitro anticancer efficacy of a polyphenolic combination of Quercetin, curcumin, and berberine in triple negative breast cancer (TNBC) cells","volume":"2","author":"Kashyap","year":"2022","journal-title":"Phytomed. Plus"},{"key":"10.1016\/j.bbrc.2025.152473_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000279","article-title":"Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies","volume":"7","author":"Blows","year":"2010","journal-title":"PLoS Med."},{"key":"10.1016\/j.bbrc.2025.152473_bib31","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2025.152473_bib32","doi-asserted-by":"crossref","first-page":"8499","DOI":"10.1007\/s11033-020-05892-8","article-title":"Berberine reverses epithelial-mesenchymal transition and modulates histone methylation in osteosarcoma cells","volume":"47","author":"Mishra","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.bbrc.2025.152473_bib33","article-title":"EMT in breast Carcinoma-A review","volume":"5","author":"Lima","year":"2016","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bbrc.2025.152473_bib34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc2620","article-title":"Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits","volume":"9","author":"Polyak","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2025.152473_bib35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ceb.2016.06.002","article-title":"Epithelial\u2013mesenchymal transition (EMT) and metastasis: yes, no, maybe?","volume":"43","author":"Diepenbruck","year":"2016","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.bbrc.2025.152473_bib36","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.2147\/CMAR.S296038","article-title":"MRPL13 promotes tumor cell proliferation, migration and EMT process in breast cancer through the PI3K-AKT-mTOR pathway","volume":"13","author":"Cai","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.bbrc.2025.152473_bib37","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1158\/0008-5472.CAN-06-1479","article-title":"Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel","volume":"67","author":"Cheng","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2025.152473_bib38","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.canlet.2010.03.003","article-title":"NF-\u03baB promotes epithelial\u2013mesenchymal transition, migration and invasion of pancreatic carcinoma cells","volume":"295","author":"Maier","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2025.152473_bib39","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.cellbio.17.1.615","article-title":"Cellular function of phosphoinositide 3-Kinase: implications for development, immunity, homeostasis, and cancer","volume":"17","author":"Katso","year":"2001","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.bbrc.2025.152473_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/13880209.2020.1865407","article-title":"Berberine regulates the Notch1\/PTEN\/PI3K\/AKT\/mTOR pathway and acts synergistically with 17-AAG and SAHA in SW480 colon cancer cells","volume":"59","author":"Li","year":"2021","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.bbrc.2025.152473_bib41","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a000141","article-title":"NF-kappaB as a critical link between inflammation and cancer","volume":"1","author":"Karin","year":"2009","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.bbrc.2025.152473_bib42","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1046\/j.1523-1755.1998.00202.x","article-title":"Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line","volume":"54","author":"Healy","year":"1998","journal-title":"Kidney Int."},{"key":"10.1016\/j.bbrc.2025.152473_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12090882","article-title":"Enhanced intestinal absorption and pharmacokinetic modulation of berberine and its metabolites through the inhibition of P-Glycoprotein and intestinal metabolism in rats using a berberine mixed micelle formulation","volume":"12","author":"Kwon","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbrc.2025.152473_bib44","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00424-006-0126-x","article-title":"Structure and function of ABC transporters: the ATP switch provides flexible control","volume":"453","author":"Linton","year":"2007","journal-title":"Pfl\u00fcgers Archiv"},{"key":"10.1016\/j.bbrc.2025.152473_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/biom10010051","article-title":"Development of human monoclonal antibody for Claudin-3 overexpressing carcinoma targeting","volume":"10","author":"Yang","year":"2019","journal-title":"Biomolecules"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2501188X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X2501188X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:24:21Z","timestamp":1775834661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X2501188X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":45,"alternative-id":["S0006291X2501188X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.152473","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of Berberine and NVP-BEZ235 inhibits metastasis of triple-negative breast cancer MDA-MB-231 cell line","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.152473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152473"}}